Business Daily Media

Immuno Cure BioTech acquires Shanghai Teresa Healthcare

  • Written by Business Daily Media

Integrating Electroporation Technology & DNA Vaccine Platforms

HONG KONG SAR - Media OutReach - 20 September 2022 - Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park specialising in DNA vaccines and immunotherapies, announced today the acquisition of 92.6% of Shanghai Teresa Healthcare, the pioneer of electroporation technology and device in China.

The transaction will be settled in cash and shares. Teresa's shareholders will swap for about 1.5% equity in Immuno Cure while the inventor of Teresa's EP technology, Professor XU Yuhong (徐宇虹), maintains her 7.4% direct equity in Teresa.

Teresa EP device delivers brief electrical pulses to promote efficient penetration of DNA vaccine through cell membrane for the enhancement of gene expression and ultimate immune responses. It is the only such device approved by National Medical Products Administration for the administration of DNA vaccine in China. Such EP technology has been an integral part of Immuno Cure's DNA vaccine delivery strategy from research to clinical stage.

Founded in 2004, Shanghai Teresa is an innovative medical device group focusing in electro immunotherapies and rehabilitation therapies. In 2005, Teresa's electroporation technology was developed to enhance the delivery of DNA medicine, based on the intellectual property generated by Shanghai Jiao Tong University under the National 863 Project. Such EP technology has been proven safe and efficacious after deployment of over 10,000 times in collaboration with more than thirty hospitals for the administration of DNA medicine in numerous human trial subjects.

Immuno Cure has two PD-1-Enhanced DNA vaccines currently in phase 1 clinical trial for prevention of COVID-19 and therapeutic cure of HIV/AIDS.

Dr JIN Xia, CEO of Immuno Cure said, "Immuno Cure has partnered with Teresa over the years in developing customised EP delivery strategy for our PD-1-Enhanced DNA vaccines, which has brought about encouraging results in clinical setting recently. I am pleased with this convergence with Teresa, which will no doubt bring our teams even closer together. Teresa will continue to operate independently while leveraging on Immuno Cure's R&D platform for the development of their next generation non-invasive EP technology for intradermal delivery strategy. Immuno Cure is committed to support the continual growth and success of Teresa."

Ms. CHEN Liye, CEO of Teresa said, "Founded on our long term collaboration, Teresa is excited to become a member of Immuno Cure Group. This move will not only provide us with a much closer R&D relationship, which is essential for our technology advancement but also offer us the financial capability to meet future needs. Teresa treasures our collaborations with other players in the field and look forward to continuing our collaborations with new and sustainable EP technology."

Professor CHEN Zhiwei, Director of AIDS Institute at the University of Hong Kong and the Principal Scientific Advisor of Immuno Cure said, "Our research and development work at the AIDS Institute and Immuno Cure has benefitted from Teresa's EP technology and their diligent collaborative effort over the past 12 years. I am pleased to see their relationship developing into an even closer tie. Look forward to the development of the next generation of EP technology for further optimisation of delivery strategy and patient experience."

Dr Percy CHENG, Chairman of Immuno Cure concludes, "This transaction offers Immuno Cure the opportunity to secure Teresa's EP technology for support of not only R&D but also the clinical administration of our PD-1-Enhanced DNA vaccines. We are pleased with Professor XU's decision to remain as our co-investor in Teresa and are optimistic in the future of EP technology in our DNA vaccine development."Hashtag: #ImmunoCureBiotech

The issuer is solely responsible for the content of this announcement.

Immuno Cure BioTech

Immuno Cure BioTech is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of vaccines and immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-Enhanced DNA vaccine and Anti-Δ42PD1 Blocking Antibody technology platforms.

To learn more about Immuno Cure BioTech, please visit

Shanghai Teresa Healthcare

Founded in 2004, Shanghai Teresa is an innovative medical device group based in Shanghai Zhangjiang Hi-Tech Park, focusing in electro immunotherapies and rehabilitation therapies.

To learn more about Shanghai Teresa Healthcare, please visit




News from Asia

Daiwa and Morgan Stanley Reaffirm "Buy" Rating on Fosun

Both Firms Believe Fosun’s Cash Position is Sufficient to Repay its Debts Obligations HONG KONG SAR - Media OutReach - 23 September 2022 - Recently, a number of investment banks have expressed ...

OPPO Holds "Design in Tech" Workshop, Interpreting Innovative and Elegant Design Aesthetics of OPPO Products

Principal of Zaha Hadid Architects, RCA Professor Gather to Discuss the Fusion of Technology and Design LONDON, UK - Media OutReach - 23 September 2022 - OPPO presented at the 2022 London Design F...

Title Sponsored by Hysan Development: Celebrating the 65th Anniversary of YAM-PAK-TONG’s Floral Princess

A Collection of Coeng-ping Images 65 ; October 16 – 25, 2022 at Lee Theatre Plaza A Photographic Recreation of Princess Coeng-ping's Special Qualities with A Modern Twist HONG KONG SAR - Media...

The Enabling Festival 2022 (賦智生活节) opens for the fifth year, aims to support a dementia-friendly Singapore through The Power of Touch

SINGAPORE - Media OutReach - 23 September 2022 - The Enabling Festival 2022 opens on 23 September 2022 at National Gallery Singapore, with the key programme focus on the theme of Touch...

Blockbuster enters the area-the first round IDO of the world's first Web3 ecological exchange BIB is starting

TAIPEI, TAIWAN - Media OutReach - 23 September 2022 - Web3 era has given birth to a new business model. On the eve of the change, BIB Exchange, an innovative trading platform in the Web3, was laid...

TRON Founder Justin Sun Speaks at UDC: TRON Ecosystem Leads the Way to Web 3.0 with Its User Base Expectedly Growing to Compete with Ethereum Next Year

GENEVA, SWITZERLAND - Media OutReach - 23 September 2022 - On the morning of September 23, TRON founder Justin Sun attended Upbit Developer Conference (UDC) in South Korea and delivered a keynote ...

BingX Becomes the First Crypto Exchange to Offer Copy Trading Subsidy Vouchers

SINGAPORE - Media OutReach - 23 September 2022 - BingX, the leading social trading exchange, has become the first crypto platform to introduce copy trading subsidy vouchers. These help to cover l...

Empowering Change Leaders to Face Advance Challenges of Modern Technology: National University of Singapore Postgraduate by Coursework Fair (NUS PGCF) 2022

Extending in-depth and high-quality multidisciplinary, future-oriented postgraduate by coursework programmes offered by NUS through a virtual event featuring 14 booths, 14 masterclass sessions, 23 ...

Bitkub Exchange and Bitkub Academy partner with TRON to develop Learning Airdops and host the NewTRON : Pitching Competition.

GENEVA, SWITZERLAND - Media OutReach - 24 September 2022 - Bitkub Online Co., Ltd. and Bitkub Labs Co., Ltd. has announced the marketing partnership with TRON, a leading global blockchain network ...

The Eighth Tourism Development Conference of Shanxi Province in 2022 and the 33rd Guangong Cultural Tourism Festival Were Successfully Held in Yuncheng City

HONG KONG SAR - Media OutReach - 25 September 2022 - Sponsored by the Shanxi Provincial Party Committee and the Provincial Government, hosted by the Shanxi Provincial Department of Culture and Tou...

Business Reports

Why Patagonia's purpose-driven business model is unlikely to spread

Patagonia has always sought to limit its environmental harm.Budrul Chukrut/SOPA Images/LightRocket via Getty ImagesPatagonia founder Yvon Chouinard, his wife, Malinda, and their two adult children no longer own the outdoor gear an...

Why does money exist?

Cash is pretty convenient.Dilok Klaisataporn/EyeEm via Getty ImagesCurious Kids is a series for children of all ages. If you have a question you’d like an expert to answer, send it to curiouskidsus@theconversation.com.Why do...

Castellum is among the first to receive NollCO2 certification

The Korsningen block project has now been completed, and Castellum is one of the first companies in the Nordics to receive a NollCO2 (ZeroCO2) certification. The Swedish Police Authority, the tenant in the project, has...

Minomic records breakthrough commercial sale in the US

Australian diagnostics company Minomic International Ltd (Minomic) is pleased to announce that their lead product, MiCheck® Prostate,1 has recorded its initial commercial sales in the US, the world’s largest healthcare mark...

Corporate Traveller and Rex Airlines partnership a game-changer for SMEs

In a move that demonstrates a strong and game-changing commitment to the Australian SME sector, Flight Centre Travel Group’s flagship SME business, Corporate Traveller, has partnered with Rex Airlines, Australia’s larges...

5 Ways to stay germ free on a plane

In pre-Covid days, no one gave much thought to their health when travelling, but nowadays, maintaining good hygiene while travelling has never been more important.  If you have ever had the misfortune of sitting on a plane and...

Web Busters - Break into local search

WebBusters.com.au